漳州片仔癀药业股份有限公司 漳州片仔癀药业股份有限公司董事、监事和高级管理人员 关于公司 2023 年半年度报告的确认意见 根据《中华人民共和国证券法（2019 年修订）》《公开发行证券的公 司信息披露内容与格式准则第 3 号——半年度报告的内容与格式》（2021 年修订）》和《上海证券交易所股票上市规则（2023 年修订）》等相关规 定和要求，作为漳州片仔癀药业股份有限公司的董事、监事和高级管理人 员，我们在全面了解和审核《公司 2023 年半年度报告》后，发表意见如 下： 董事、监事和高级管理人员 2023 年 8 月 17 日 1、 公司严格按照股份制公司的财务制度规范运作，公司 2023 年半 年度报告的编制符合法律、行政法规、《漳州片仔癀药业股份 有限公司章程》及公司内部管理制度的各项规定，2023 年半年 度报告公允、真实、全面地反映了公司 2023 年半年度报告的财 务状况和经营成果。 2、 公司第七届董事会第十四次会议、第七届监事会第九次会议审 议通过《公司 2023 年半年度报告及摘要》的议案。 3、 公司全体董事、监事和高级管理人员保证《公司 2023 年半年度 报告及摘要》所披露的信息真 ...

证券代码：600436 证券简称：片仔癀 公告编号：2023-026 审计委员会：贾建军（主任委员）、杜守颖、赖文宁 提名委员会：李广培（主任委员）、林纬奇、范志鹏、杜守颖 1 / 2 漳州片仔癀药业股份有限公司 关于调整董事会专门委员会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）原独立董事 贾建军先生、李广培先生于2017年8月起，连任公司独立董事时间达 到六年，任期届满。上述两位独立董事向公司董事会提请辞去独立董 事及董事会下属专门委员会相关职务。公司于2023年5月22日召开第 七届董事会第十一次会议，审议通过《公司关于选举独立董事的议 案》，会议增补陈蕾女士、张磊先生为公司第七届董事会独立董事候 选人，并经2023年6月15日的2022年年度股东大会审议通过。 公司原董事长林纬奇先生因工作调整，向董事会辞去公司董事、 董事长及董事会下属专门委员会委员等职务。公司于2023年7月24日 召开第七届董事会第十二次会议，审议通过《公司关于增补董事的议 案》，会议增补林 ...

表决结果：8 票同意，0 票反对，0 票弃权。 证券代码：600436 证券简称：片仔癀 公告编号：2023-025 漳州片仔癀药业股份有限公司 第七届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）第七届董事 会第十三次会议于 2023 年 8 月 9 日（星期三）下午 16:30 以现场与 通讯相结合方式在芗江酒店一楼芗江 A 厅会议室召开。会议通知和议 案以专人送达、电子邮件方式发出。本次会议应参加表决董事 8 人， 实际表决董事 8 人。经全体董事同意，本次会议豁免通知时限要求。 经半数以上董事推举，会议由董事林志辉先生主持。本次会议召开符 合《公司法》与《漳州片仔癀药业股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，合法、有效。到会董事以通讯方式表决， 审议以下议案： 一、 审议通过《公司关于选举董事长的议案》； 特此公告。 漳州片仔癀药业股份有限公司 董 事 会 为规范公司运作，完善法人治理结构，根据《公司章程》等相关 规定，董事 ...

证券代码：600436 证券简称：片仔癀 公告编号：2023-024 漳州片仔癀药业股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 369 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 413,149,793 | | 3、出席会议的股东所持有表决权股份数占公司有表 | 68.4797 | | 决权股份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主 持情况等。 1 (一) 股东大会召开的时间：2023 年 8 月 9 日 (二) 股东大会召开的地点：漳州市芗城区漳州芗江酒店二楼凌波厅 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有 股份情况： 表决方式符合《公司法》及《漳州片仔癀药业股份有限公司章程》 （以下简称"《公司章程》"）的规定，公司董事黄进明先生主持本次 会议。大会采用网络投票和现场投票相 ...

泰和泰证字[2023]PZH-02 号 泰和泰（北京）律师事务所 北京市朝阳区东四环中路 56 号远洋国际中心 A 座 12 层 电话：（010）85865151 传真：（010）85861922 邮政编码：100025 泰和泰（北京）律师事务所关于漳州片仔癀药业股份有限公司 2023 年第一次临时股东大会法律意见书 泰和泰（北京）律师事务所 关于漳州片仔癀药业股份有限公司 2023 年第一次临时股东大会 法律意见书 泰和泰（北京）律师事务所 关于漳州片仔癀药业股份有限公司 2023 年第一次临时股东大会法律意见书 泰和泰证字[2023]PZH-02 号 致：漳州片仔癀药业股份有限公司 泰和泰（北京）律师事务所（以下简称"本所"）接受漳州片仔癀药业股份 有限公司（以下简称"公司"）的委托，指派许军利律师、殷庆莉律师对公司 2023 年第一次临时股东大会（以下简称"本次股东大会"）进行见证，并依据 《中华人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管理委 员会《上市公司股东大会规则》（以下简称"《股东大会规则》"）、《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》（以下简称"《规范运 ...

证券代码：600436 证券简称：片仔癀 公告编号：2023-012 漳州片仔癀药业股份有限公司 关于参加福建辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，漳州片仔癀药业股份有限公 司（以下简称"公司"）将参加由福建证监局、福建省上市公司协会 与深圳市全景网络有限公司联合举办的"2023 年福建辖区上市公司 投资者网上集体接待日活动"。现将相关事项公告如下： 本次集体接待日活动将采用网络远程的方式举行，投资者可以登 录"全景路演"网站（http://rs.p5w.net/），或关注微信公众号"全 景财经"，或下载全景路演 APP，参与本次互动交流。 活动时间为 2023 年 5 月 15 日（星期一）16:00 至 17:30。 届时，公司高管将在线就公司 2022 年度及 2023 年第一季度的业 绩情况、公司治理、发展战略、经营状况和可持续发展等投资者关心 的问题，与投资者进行沟通与交流。 欢迎广大投资者踊跃参与！ 特此公告。 漳 ...

2022年年度报告 公司代码：600436 公司简称：片仔癀 漳州片仔癀药业股份有限公司 ...

2023年第一季度报告 证券代码：600436 证券简称：片仔癀 漳州片仔癀药业股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

2022 年第三季度报告 证券代码：600436 证券简称：片仔癀 漳州片仔癀药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律 责任。 公司负责人林纬奇、主管会计工作负责人杨海鹏及会计机构负责人（会计主管人 员）何麟保证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 1 / 20 2022 年第三季度报告 单位：元币种：人民币 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|-------------------|---------------------------------------|-------------------|- ...

Financial Performance - The company's operating revenue for the first half of 2022 reached ¥4,422,632,056.64, representing a 14.91% increase compared to ¥3,848,706,002.12 in the same period last year[11]. - The net profit attributable to shareholders of the listed company was ¥1,314,364,302.27, up 17.85% from ¥1,115,239,605.23 in the previous year[11]. - The net cash flow from operating activities significantly increased to ¥5,364,583,037.99, a remarkable rise of 1,794.16% compared to ¥283,216,344.17 in the same period last year[11]. - The total assets of the company at the end of the reporting period were ¥13,545,163,644.18, an increase of 8.40% from ¥12,495,334,742.42 at the end of the previous year[11]. - The net assets attributable to shareholders of the listed company increased by 5.32% to ¥10,221,163,178.71 from ¥9,705,010,875.84 at the end of the previous year[11]. - Basic earnings per share for the first half of 2022 were ¥2.18, reflecting a 17.84% increase from ¥1.85 in the same period last year[12]. - The weighted average return on net assets decreased by 0.50 percentage points to 12.73% from 13.23% in the previous year[12]. Risk Management - The company has not reported any significant risks that could materially affect its operations during the reporting period[2]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[2]. - The company faces potential risks including policy changes that could affect tax rates, currently benefiting from a reduced corporate income tax rate of 15%[60]. - The company has invested in R&D to maintain its status as a high-tech enterprise, which is crucial for mitigating risks associated with tax policy changes[60]. - The company is actively managing environmental risks through innovation and compliance with stricter regulations[62]. - The company is preparing for potential raw material supply and price risks by strategically increasing procurement reserves[63]. Corporate Governance - The company held two shareholder meetings in the reporting period, with all resolutions passed without dissent[66]. - The first extraordinary shareholder meeting approved various reports and proposals, including the work reports of the sixth board of directors and supervisors[66]. - The company appointed Chen Honghui as the secretary of the board of directors in August 2022[70]. - The company experienced changes in its board and supervisory personnel, with several new appointments made during the reporting period[67][68]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[71]. - The company’s governance structure was improved through the election of new board members and supervisors in January 2022[69]. Environmental Responsibility - The company achieved a 100% compliance rate in environmental monitoring and a 100% guarantee rate for environmental protection funding during the reporting period[38]. - The company was listed as a key pollutant discharge unit in Zhangzhou City for 2021, with all emissions meeting the required standards[72]. - The company reported a total discharge of 0.66454 tons of COD, 0.01321 tons of ammonia nitrogen, and 0.1453 tons of sulfur dioxide, all within regulatory limits[72]. - The company has established a comprehensive hazardous waste management plan for 2022, ensuring proper disposal of industrial solid waste and hazardous waste by qualified companies[75]. - Environmental monitoring results indicate that all pollutants from Pianzaihuang Cosmetics are within the limits set by relevant standards, including noise and odor emissions[75]. - The company has committed to continuous improvement in environmental performance, including regular monitoring and third-party assessments of pollutant emissions[80]. Research and Development - The company has established a management system for drug marketing authorization holders (MAH) since 2021, adding new products like Apixaban tablets in 2022[21]. - The company is focusing on the R&D of innovative traditional Chinese medicine, with plans to enhance the clinical and market value of its key products like Pian Zai Huang[27]. - The company has a strong commitment to technology innovation, being recognized as a national high-tech enterprise and continuously expanding its R&D capabilities[24]. - The company reported a significant increase in R&D expenses, which rose by 82.18% year-on-year, amounting to CNY 11,012.15 million[41]. - The company is actively advancing new drug research, including PZH2111 for intrahepatic cholangiocarcinoma and PZH2108 for cancer pain, among others, establishing a robust pipeline for future growth[28]. Market Expansion and Product Development - The company aims to enhance its core competitiveness by implementing a "multi-core drive, dual development" strategy in the health industry[17]. - The company has successfully launched the "Pian Zai Huang" brand An Gong Niu Huang Wan, which has gained significant consumer trust[19]. - The company is expanding its product line, including various medications for liver disease, colds, and skin conditions, with a valid drug production license until November 2025[19]. - The company’s pharmaceutical distribution business is focused on modern logistics and aims to extend its distribution chain[19]. - The company is expanding its brand influence through high-frequency advertising campaigns, including collaborations with major media outlets and innovative promotional events[34]. Financial Position - The total assets of the company at the end of the reporting period are not explicitly stated but can be inferred to be substantial given the equity figures reported[111]. - The company's total equity reached ¥10,685,559,425.27, compared to ¥10,136,749,207.49, an increase of approximately 5.4%[97]. - The company's retained earnings increased to ¥7,283,359,137.54 from ¥6,699,008,659.37, showing a growth of approximately 8.7%[97]. - The total liabilities increased to ¥2,859,604,218.91, up from ¥2,358,585,534.93, representing a growth of approximately 21.2%[97]. - Cash and cash equivalents decreased to ¥1,853,952,795.22 from ¥5,966,010,997.85, a decline of approximately 68.9%[98]. Social Responsibility - The company is committed to social responsibility, engaging in various community support initiatives and health-related donations during the pandemic[34]. - The company actively supports poverty alleviation and rural revitalization, providing technical support and funding to livestock farmers in collaboration with local governments[85]. - During the reporting period, the company donated funds to 30 underprivileged families and organized various charitable activities, including donations to welfare institutions for children with severe illnesses[85]. - The company continues to focus on high-quality development while fulfilling its social responsibilities[85].